FOLFOXIRI—improving outcomes of metastatic colorectal cancer

被引：0
|
作者：
Alessia Errico
机构：
来源：
Nature Reviews Clinical Oncology | 2014年 / 11卷 / 12期
关键词：
D O I：
10.1038/nrclinonc.2014.194
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：684 / 684
相关论文
共 50 条
  • [41] Management of FOLFOXIRI and Bevacizumab therapy for colorectal cancer patients
    Kagawa, Yoshinori
    Naito, Atsushi
    Kawai, Kenji
    Mori, Ryota
    Sakamoto, Takuya
    Murakami, Kohei
    Katsura, Yoshiteru
    Omura, Yoshiaki
    Masuzawa, Toru
    Takeno, Atsushi
    Takeda, Yutaka
    Kato, Takeshi
    Murata, Kohei
    [J]. CANCER SCIENCE, 2018, 109 : 673 - 673
  • [42] Amlodipine improves the outcomes of regorafenib in metastatic colorectal cancer
    Alandag, Celal
    Karaman, Elanur
    Yuce, Elif
    [J]. ANTI-CANCER DRUGS, 2022, 33 (04) : 389 - 393
  • [43] Treatment patterns and outcomes in metastatic colorectal cancer (mCRC).
    Cartwright, Thomas H.
    Wen, Lonnie Kent
    Harrell, Robyn K.
    Fox, Patricia S.
    Espirito, Janet L.
    Wang, Ed
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [44] Second-line treatments in patients with metastatic colorectal cancer progressed after first-line FOLFOXIRI
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Fornaro, L.
    Salvatore, L.
    Cupini, S.
    Stasi, I.
    Brunetti, I. M.
    Andreuccetti, M.
    Falcone, A.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 346 - 347
  • [45] SECOND-LINE TREATMENTS IN PATIENTS WITH METASTATIC COLORECTAL CANCER PROGRESSED AFTER FIRST-LINE FOLFOXIRI
    Fornaro, Lorenzo
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Salvatore, Lisa
    Stasi, Irene
    Baldi, Giacomo Giulio
    Cupini, Samanta
    Barbara, Cecilia
    Pfanner, Elisabetta
    Brunetti, Isa Maura
    Di Donato, Samantha
    Caponi, Sara
    Allegrini, Giacomo
    Antonuzzo, Andrea
    Ricci, Sergio
    Chiara, Silvana
    Vitello, Stefano
    Andreuccetti, Michele
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [46] FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
    Alexander Stein
    Djordje Atanackovic
    Bert Hildebrandt
    Patrick Stübs
    Wolfram Brugger
    Gunnar Hapke
    Claus-Christoph Steffens
    Gerald Illerhaus
    Ernst Bluemner
    Jan Stöhlmacher
    Carsten Bokemeyer
    [J]. British Journal of Cancer, 2015, 113 : 872 - 877
  • [48] Effectiveness and tolerability of FOLFOXIRI regimen in the third- and subsequent lines of therapy in patients with metastatic colorectal cancer.
    Yakimovich, Kseniya
    Alaniya, Mariya
    Shilo, Polina
    Mochalova, Anastasia
    Ledin, Evgeny
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Upfront FOLFOXIRI plus bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
    Stein, Alexander
    Atanackovic, Djordje
    Hildebrandt, Bert
    Stuebs, Patrick
    Brugger, Wolfram
    Hapke, Gunnar
    Steffens, Claus-Christoph
    Illerhaus, Gerald
    Bluemner, Ernst
    Stoehlmacher, Jan
    Bokemeyer, Carsten
    [J]. BRITISH JOURNAL OF CANCER, 2015, 113 (06) : 872 - 877
  • [50] Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
    Yosuke Kito
    Hironaga Satake
    Hiroya Taniguchi
    Takeshi Yamada
    Yoshiki Horie
    Taito Esaki
    Tadamichi Denda
    Hisateru Yasui
    Naoki Izawa
    Toshiki Masuishi
    Toshikazu Moriwaki
    Keita Mori
    Kentaro Yamazaki
    [J]. Cancer Chemotherapy and Pharmacology, 2020, 86 : 277 - 284
12345